Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in research, development, production, and sales of blood products in China. Its lead products include human serum albumin, human immunoglobulin, intravenous human immunoglobulin (PH4), hepatitis B human immunoglobulin, tetanus human immunoglobulin, rabies patient immunoglobulin, and human coagulation factor. addition, it engages in the investment, consultation, and technology promotion of pharmaceutical and biotechnology development projects; and electronic product information consultation. The company was formerly known as Southern Shuanglin Bio-pharmacy Co., Ltd. and changed its name to Pacific Shuanglin Bio-pharmacy Co., Ltd. in April 2021. Pacific Shuanglin Bio-pharmacy Co., Ltd. was founded in 1993 and is based in Taiyuan, China.
Metrics to compare | 000403 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship000403PeersSector | |
---|---|---|---|---|
P/E Ratio | 25.7x | 40.1x | −0.5x | |
PEG Ratio | −1.53 | 0.54 | 0.00 | |
Price/Book | 2.1x | 2.5x | 2.6x | |
Price / LTM Sales | 6.7x | 7.2x | 3.3x | |
Upside (Analyst Target) | 16.0% | 5.8% | 38.9% | |
Fair Value Upside | Unlock | 12.4% | 5.4% | Unlock |